Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 206,142,674 papers from all fields of science
Search
Sign In
Create Free Account
Treprostinil 0.6 MG/ML Inhalant Solution [Tyvaso]
Known as:
Tyvaso (treprostinil 1.74 MG) per 2.9 ML Inhalant Solution
, TYVASO 1.74 MG/2.9 mL (0.6 MG/mL) Inhalant Solution
, treprostinil 1.74 mg in 2.9 mL ORAL INHALANT [TYVASO]
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
10 relations
Hydrochloric Acid
Inhalant Solution
Sodium Chloride
Sodium Hydroxide
Expand
Broader (2)
Treprostinil 0.6 MG/ML Inhalant Solution
Treprostinil Inhalant Solution [Tyvaso]
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
INSPIRE: Final Results from a Phase 3, Open-Label, Pivotal Study to Evaluate the Safety and Tolerability of LIQ861 in Pulmonary Arterial Hypertension.
N. Hill
,
J. Feldman
,
+4 authors
T. Bull
The Journal of heart and lung transplantation…
2020
Corpus ID: 216443394
2019
2019
INSPIRE: A Phase 3 Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of LIQ861 in Pulmonary Arterial Hypertension (PAH) (Investigation of the Safety and Pharmacology of Dry Powder…
N. Hill
,
J. Feldman
,
+4 authors
T. Bull
The Journal of Heart and Lung Transplantation
2019
Corpus ID: 88126231
2014
2014
Prolonged activity of inhaled treprostinil prodrug nanoparticles in a rat model of pulmonary arterial hypertension
F. Leifer
,
D. M. Omiatek
,
+7 authors
W. Perkins
2014
Corpus ID: 70820087
Introduction : Inhaled treprostinil (Tyvaso™) for pulmonary arterial hypertension (PAH) is dosed 4 times daily. In an effort to…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE